Advance Authorization 2026: New Self-Ratification for Pharma Units
DGFT introduces self-ratification norms for pharma exporters under Advance Authorization. Learn eligibility and how to claim duty-free raw material imports.
Key points
The Directorate General of Foreign Trade (DGFT) has issued Notification No. 24/2026-27 on August 7, 2026, introducing a streamlined self-ratification scheme specifically for pharmaceutical exporters. Under this update, manufacturers holding a valid 3-year track record and AEO status can now self-certify their input-output norms without waiting for the Norms Committee's prior approval. This significantly reduces the lead time for obtaining an Advance Authorization license for high-value pharma ingredients.
What this means for exporters
This move is a major win for SMEs in the chemical and drug manufacturing sector. By opting for self-ratification, you can import raw materials duty-free immediately based on your technical estimates. This improves cash flow and allows for faster turnaround on international orders. However, post-export audits will be stringent, ensuring that the input-output ratios used are scientifically justifiable.
Who should act now: Established pharmaceutical manufacturers with AEO T2 status or higher should review their existing norm applications.
At We Design For You, we specialize in DGFT documentation and Advance Authorization filing. Contact us today to check your eligibility for the self-ratification scheme and ensure your technical data meets the new audit standards.